Anthroposophic therapy for attention deficit hyperactivity: a two-year prospective study in outpatients

Harald J Hamre1
Claudia M Witt2
Gunver S Kienle1
Christoph Meinecke3
Anja Glockmann1
Renatus Ziegler4
Stefan N Willich2
Helmut Kiene1

1Institute for Applied Epistemology and Medical Methodology, Freiburg, Germany; 2Institute of Social Medicine, Epidemiology, and Health Economics, Charité University Medical Center, Berlin, Germany; 3Pediatric Consultant, Community Hospital Havelhöhe, Berlin, Germany; 4Society for Cancer Research, Arlesheim, Switzerland

Correspondence: Harald J Hamre
IFAEMM, Zechenweg 6, D-79111 Freiburg, Germany
Tel +49 761 156 0307
Fax +49 761 156 0306
Email harald.hamre@ifaemm.de

Background: Anthroposophic treatment for attention deficit hyperactivity disorder (ADHD) includes special artistic and physical therapies and special medications.

Methods: We studied 61 consecutive children starting anthroposophic treatment for ADHD symptoms under routine outpatient conditions. Primary outcome was FBB-HKS (a parents’ questionnaire for ADHD core symptoms, 0–3), and secondary outcomes were disease and symptom scores (physicians’ and parents’ assessment, 0–10) and quality of life (KINDL® total score, 0–100).

Results: A total of 67% of patients fulfilled the DSM-IV criteria for ADHD, 15% had an exclusion diagnosis such as pervasive developmental disorders, while 18% did not fulfill ADHD criteria for another reason. Anthroposophic treatment modalities used were eurythmy therapy (in 56% of patients), art therapy (20%), rhythmical massage therapy (8%), and medications (51%). From baseline to six-month follow-up, all outcomes improved significantly; average improvements were FBB-HKS total score 0.30 points (95% confidence interval [CI]: 0.18–0.43; P < 0.001), FBB-HKS inattention 0.36 (95% CI: 0.21–0.50; P < 0.001), FBB-HKS hyperactivity 0.29 (95% CI: 0.14–0.44; P < 0.001), FBB-HKS impulsivity 0.22 (95% CI: 0.03–0.40; P < 0.001), disease score 2.33 (95% CI: 1.84–2.82; P < 0.001), symptom score 1.66 (95% CI: 1.17–2.16; P < 0.001), and KINDL 5.37 (95% CI: 2.27–8.47; P = 0.001). Improvements were similar in patients not using stimulants (90% of patients at months 0–6) and were maintained until last follow-up after 24 months.

Conclusion: Children with ADHD symptoms receiving anthroposophic treatment had long-term improvement of symptoms and quality of life.

Keywords: anthroposophy, attention deficit disorder with hyperactivity, combined modality therapy, prospective studies, quality of life

Background
Symptoms of inattention, hyperactivity, and impulsivity are reported in 8%–16% of children,1,2 and 5% of all children fulfill the diagnostic criteria for attention deficit hyperactivity disorder (ADHD).3 ADHD can affect self-esteem, social skills, parent–child relationships, and school performance, and is associated with psychiatric comorbidity.4,5 In clinical trials, central stimulants and related medications improve ADHD symptoms.7 However, up to 30% of children do not respond to or do not tolerate stimulants due to adverse effects,8 and less than 10% continue with stimulants after one year.9 Psychosocial interventions are less effective than medications but provide modest benefits as add-ons.10,11 Up to two-thirds of children with ADHD use complementary or alternative therapies,12 sometimes provided by their physicians.
Anthroposophic medicine (AM) is a complementary system of medicine, founded by Rudolf Steiner and Ita Wegman. AM is provided by specially trained physicians in 56 countries worldwide. AM extends the conception of human physiology beyond cellular and molecular mechanisms to holistic interactions of overriding functional systems (downward causality). In particular, a complex equilibrium exists between two polar systems, ie, the “nerve-sense system” (low metabolic rate, mediator of consciousness) and the “metabolic-limb system” of the abdominal organs and limbs (high metabolic rate, minimal consciousness, mediator of voluntary movement). This equilibrium can be distorted in human disease. For example, the ADHD symptom of hyperactivity is seen to reflect a predominance of 12–15 sessions of 45 minutes each, administered once weekly. Between therapy sessions the patients perform eurythmy movements daily.

Eurythmy (Greek, meaning “harmonious rhythm”) therapy is an active exercise therapy involving cognitive, emotional, and volitional elements. During eurythmy therapy sessions, patients are instructed to perform specific movements with the hands, feet or whole body. Eurythmy movements are related to the sounds of vowels and consonants, to music intervals or to soul gestures, eg, sympathy-antipathy. A eurythmy therapy cycle usually consists of 12–15 sessions of 45 minutes each, administered once weekly. Between therapy sessions the patients perform eurythmy movements daily.

In AM art therapy, the patients engage in painting, drawing, clay modeling, music, or speech exercises. An AM art therapy cycle usually consists of 12 sessions of 45 minutes each, administered once weekly. In addition to psychologic effects (eg, activation, emotive expression, dialogic communication with the therapist and with the artistic medium), AM art therapy can induce physiologic effects, eg, AM speech exercises have effects on heart rate rhythmicity and cardiorespiratory synchronization which are not induced by spontaneous or controlled breathing alone. Eurythmy exercises have similar effects.

Rhythmic massage therapy was developed from Swedish massage by Ita Wegman, a physician and physiotherapist. In rhythmic massage therapy, traditional massage techniques (effleurage, petrissage, friction, tapotement, vibration) are supplemented by gentle lifting and rhythmically undulating, stroking movements, where the quality of grip and emphasis of movement are altered to promote specific effects. A rhythmic massage therapy cycle usually consists of 6–12 sessions administered once or twice weekly, each session lasting 20–30 minutes and followed by a rest period of at least 20 minutes. Most patients can be treated with one cycle of art, eurythmy, or massage therapy, while prolonged treatment may be necessary for some patients with severe or persistent disease.

AM medications are prepared from plants, minerals, animals, and from chemically defined substances, and can be prepared in concentrated or potentized form. Potentization implies a successive dilution, each dilution step involving a rhythmical succussion (repeated shaking of liquids) or trituration (grinding of solids into lactose monohydrate). For example, a D6 potency (also called 6×) has been potentized in a 1:10 dilution six times, resulting in a 1:10^-6 dilution. Because potencies beyond D23 do not contain any molecules of the original substance, effects cannot readily be explained by molecular mechanisms. However, a systematic review of in vitro studies found biologic effects of potencies ≥D23 in nearly three-quarters of the studies and in more than two-thirds of the studies with highest quality. All AM medications are manufactured according to Good Manufacturing Practice and national drug regulations. Quality standards of raw materials and manufacturing methods are described in the Anthroposophic Pharmaceutical Codex. Toxicologically relevant starting materials (eg, belladonna, lead) are highly diluted according to the safety requirements of European regulations. The available evidence suggests that AM medications and therapies are generally well tolerated, with infrequent adverse reactions of mostly mild to moderate severity.

Prior to prescription of AM medications or referral to AM therapies, AM physicians have prolonged consultations with the patients and their caregivers. These consultations are used to take an extended history, to address constitutional and psychosocial aspect of the patients’ illness, to explore the family’s preparedness to engage in treatment, and to select optimal therapy for each patient.

AM therapy providers (physicians, physiotherapists, eurythmy therapists, art therapists) are certified following structured training programs according to international, standardized curricula. Therapy guidelines exist for AM medical therapy, eurythmy therapy, and AM art therapy.

Related to the AM approach is an educational philosophy implemented in more than 3000 Waldorf schools, kindergartens, and curative education centers worldwide, many of which provide AM therapies.

AM treatment for children with ADHD symptoms aims at general and specific effects. AM art and eurythmy exercises...
aim to develop concentration, awareness of feelings, and motor skills, whereas rhythmical massage therapy works through sensory stimulation. All three therapy modalities (art, eurythmy, rhythmical massage) aim at psychologic effects from verbal and nonverbal communication with therapists, while all AM treatment aims to regulate the equilibrium between the nerve-sense system and the metabolic-limb system. In addition, AM treatment aims at more specific effects on individual ADHD symptoms and constitutional features by employing specific art therapy modalities, specific eurythmy movements, specific massage techniques, specific massage movement patterns, and specific AM medications (further descriptions are available). AM medications do not contain chemicals with stimulant properties, such as for conventional central nervous system sympathomimetics.

AM physicians treating children with ADHD symptoms will give information and advice to the family, teachers, and other caregivers about the condition, natural history, coping and management strategies, and treatment options, and they will assess the kindergarten or school situation. In addition, the physicians will choose among the available AM therapy modalities, including a broad range of AM medications, in order to tailor treatment to the individual needs of the patient. Similar to recent guideline recommendations, stimulants are not used as initial therapy for moderate ADHD. In severe or nonresponsive ADHD, however, AM therapies are often combined with stimulants.

In this respect, there has been some debate among AM physicians as to the degree of severity necessitating stimulant therapy.

Two small single-center studies have evaluated AM painting/drawing/clay therapy and eurythmy therapy for ADHD. We present here a preplanned subgroup analysis of children with ADHD symptoms from a multicenter study of a broader range of AM therapy options (all artistic therapy modalities, eurythmy therapy, rhythmical massage, and medications).

For complementary therapy systems in widespread use, regardless of whether evidence from randomized trials exists, it has been argued that the conventional drug research strategy, starting with studies of biologic mechanisms and moving through Phase I, II, and III clinical trials, is not optimal. Another more appropriate strategy has been proposed, moving from descriptive studies (Phase I) towards comparative studies of the whole system and its parts, and ending with studies of biologic mechanisms (Phase V). In the context of this reversed strategy, the present analysis addressed topics in the Phases I and II (therapy paradigms, therapy use, clinical outcomes, perceived benefit, and safety).

**Methods**

**Study design**

This was a prospective, observational, two-year, cohort study in a routine outpatient medical setting. The study was part of a research project on the effectiveness, costs, and safety of AM therapies in outpatients with chronic disease (Anthroposophic Medicine Outcomes Study [AMOS]). The AMOS project was initiated by a health insurance company in conjunction with a health benefit program. The present preplanned subgroup analysis concerned a subgroup of children with ADHD symptoms. Since only limited data on AM treatment for this indication were available, the primary objective was to describe the AM therapy for ADHD symptoms (spectrum of AM therapy modalities used, extent of combination with conventional therapy) as well as the clinical outcome under AM treatment in routine outpatient settings. Further research questions addressed adverse reactions and therapy satisfaction.

**Setting, participants, and therapy**

All physicians certified by the Physicians’ Association for Anthroposophical Medicine in Germany and working in an office-based practice or outpatient clinic were invited to participate in the AMOS study. Certification as an AM physician requires a completed medical degree and a three-year structured postgraduate training. The participating physicians recruited consecutive patients starting AM therapy under routine clinical conditions. AMOS patients were included in the present analysis if they fulfilled the eligibility criteria.

Inclusion criteria were: age 3–16 years; enrolment in AMOS in the period 01 April 2001 to 31 December 2005 (the primary outcome of the present analysis was not documented for AMOS patients enrolled before April 2001); ADHD symptoms of at least six months’ duration; starting AM therapy for ADHD symptoms: starting AM medical treatment (AM-related consultation of at least 15 minutes followed by new prescription of AM medication) or referral to AM therapy by a nonmedical therapist (art, eurythmy, or rhythmical massage).

Patients were excluded if they had previously received the AM therapy in question for ADHD symptoms. AM therapy was administered at the discretion of the physicians and therapists, and evaluated as a whole system with subgroup analysis of evaluable therapy modality groups. Therapies documented in the study were classified as AM therapy (consultations with AM physicians, AM art therapy, eurythmy therapy, rhythmical massage therapy, AM medications); conventional therapy for ADHD symptoms (central stimulants,
antidepressants, psychotherapy, occupational therapy, play therapy); or other (all other therapies).

**Clinical assessments**

**Baseline assessment**

Diagnostic criteria for ADHD according to the *Diagnostic and Statistical Manual of Mental Disorders, 4th Edition* (DSM-IV) and the *International Statistical Classification of Diseases and Related Health Problems, 10th Revision* (ICD-10) were assessed using the Diagnostic Checklist for Hyperkinetic Disorders/ADHD (DCL-HKS), \(^{51}\) documented by the physicians. The DCL-HKS (revised version DCL-ADHS)\(^{52}\) is a validated checklist for the diagnosis of ADHD according to DSM-IV and ICD-10, recommended for clinical assessment of children and adolescents with ADHD symptoms in primary care.\(^{8,42}\) The DCL-HKS comprises the following items:

- A total of 18 core symptoms of ADHD, ie, inattention (nine symptoms), hyperactivity (five symptoms), and impulsivity (four symptoms)
- Additional ADHD criteria according to DSM-IV and ICD-10, ie, symptoms beginning before age seven years, presence in more than one situation, significant impairment in social, academic, or occupational functioning, symptoms not explained by age, developmental condition, school strain, very high intelligence, chaotic environment, or medication
- Exclusion diagnoses for ADHD according to DSM-IV or ICD-10, ie, pervasive developmental disorder, mood disorder, anxiety disorder, schizophrenia or other psychotic disorder, or other relevant psychiatric disorder.

These items are combined into an algorithm, resulting in the DSM-IV categories: ADHD combined type; ADHD predominantly hyperactive-impulsive type; ADHD predominantly inattentive type; ADHD not otherwise specified; and ADHD criteria not fulfilled, as well as in the ICD-10 categories, ie, F90 hyperkinetic disorder fulfilled/not fulfilled, with ICD-10 subtypes.

In addition to DCL-HKS, relevant current and previous comorbid disorders were documented in free text. The DCL-HKS is part of a more comprehensive diagnostic assessment system for psychiatric disorders in children and adolescents (DISYPS).\(^{51,52}\) DISYPS comprises checklists for the investigation of disorders frequently coexisting with ADHD, such as conduct disorder and tics. These checklists were not used in the present study.

**Primary outcome**

The primary outcome was the FBB-HKS (German: Fremdbeurteilungsbogen für Hyperkinetische Störungen) at six-month follow-up. The FBB-HKS is a validated questionnaire for core ADHD symptoms according to DSM-IV and ICD-10, documented by parents.\(^{51,52}\) The FBB-HKS consists of 20 items addressing the dimensions of inattention (nine items), hyperactivity (seven items), and impulsivity (four items). Each item is rated on a numeric rating scale from 0 (“not present”) to 3 (“very strong intensity”). Scores for the three dimensions and a FBB-HKS total score are calculated as the average of the respective items (range 0–3).

**Secondary outcomes**

Secondary outcomes were disease severity, quality of life, satisfaction with therapy, and adverse reactions. Disease severity was documented by physicians (disease score) and parents (symptom score). Disease score was the physician’s global assessment of severity of ADHD symptoms using a numeric rating scale\(^{53}\) from 0 (“not present”) to 10 (“worst possible”). Symptom score was a compound measure of the symptoms for which the parents had sought medical attention for their children. At baseline, the parents documented one to six symptoms in order of decreasing importance and assessed the intensity of each symptom on a numeric rating scale from 0 (“not present”) to 10 (“worst possible”).\(^{53}\) At each follow-up, the parents documented the intensity of the same symptoms which they had documented at baseline. Symptom score was the average severity of all documented symptoms per patient at each documentation point. This score has not been validated.

Quality of life was assessed by the parents of children aged 3–7 years and by children aged 8–16 years, using the KINDL® questionnaire for measuring health-related quality of life in children and adolescents, total quality of life score (range 0–100).\(^{54}\)

Therapy outcome rating (numeric rating scale 0–10), satisfaction with therapy (numeric rating scale 0–10), and therapy effectiveness rating (“very effective”, “effective”, “less effective”, “ineffective”, or “not evaluable”) were documented by parents (effectiveness rating also by physicians) after six and 12 months.

Adverse reactions to medications or therapies were documented by parents after six, 12, 18, and 24 months and by the physicians after six months. The documentation included suspected cause, intensity (mild/moderate/severe reflecting...
no/some/complete impairment of normal daily activities, respectively), and therapy withdrawal because of adverse reactions. Serious adverse events were documented by the physicians throughout the study.

Data collection
All data were documented using questionnaires. Questionnaires used at study enrolment were handed out by the physicians, and follow-up questionnaires were issued from the study office by post. All questionnaires were returned in sealed envelopes to the study office. The physicians documented eligibility criteria, DCL-HKS, and prescription of AM therapy at baseline. The therapists documented AM therapy administration (the implementation of each therapy session was confirmed by signatures of therapists as well as parents or patients). All other items were documented by parents unless otherwise stated. Parent responses were not made available to the physicians. The diagnostic categorization of patients with respect to ADHD criteria, based on the algorithm in DCL-HKS, was performed in the study office and not by the physicians. The physicians were compensated 60 Euro per included and fully documented patient, while the patients received no compensation.

FBB-HKS, symptom score, and KINDL were documented after 0, 3, 6, 12, 18, and 24 months. Disease score was documented after 0 and six months. Medication use was documented with name of medication, administration frequency (daily, 3–6 days per week, 1–2 days per week, 1–3 days per month, < one day per month), and duration of use.

The data were entered twice by two different persons into Microsoft® Access 97 (Microsoft Corp., Redmond WA). The two datasets were compared, and discrepancies were resolved by checking with the original data.

Quality assurance, adherence to regulations
The study was approved by the Ethics Committee of the Faculty of Medicine Charité, Humboldt University, Berlin, Germany, and was conducted according to the Declaration of Helsinki and largely following the International Conference on Harmonisation Guideline for Good Clinical Practice E6. Written informed consent was obtained from all patients before enrolment. Monitoring visits, including source data verification, were performed for all physicians enrolling at least five patients into the AMOS study in the recruitment period for the present sample (58/61 patients in the present sample).

Data analysis
The data analysis was performed on all patients fulfilling the eligibility criteria, using SPSS® 14.0.1 (SPSS Inc., Chicago, IL) and StatXact® 5.0.3 (Cytel Software Corporation, Cambridge, MA). The t-test was used for continuous data. The McNemar test and Fisher’s exact test were used for binominal data. All tests were two-tailed. Missing values for clinical outcomes at follow-up assessments were replaced by the last value carried forward.

In the main analyses, clinical outcomes were analyzed with 0–6 month (primary assessment) and 0–24 month pre-post comparisons. In an alternative set of analyses, clinical outcomes were analyzed with repeated measures analysis of variance (ANOVA) testing for within-subject change between the time points 0, three and six months, and 0 and 12, 18, and 24 months, respectively. Results were very similar to the pre-post analyses, and are not presented.

Statistical significance was set at $P < 0.05$. Since this was a descriptive study, no adjustment for multiple comparisons was performed. Pre-post effect sizes were calculated as standardized response mean (= mean change score divided by the standard deviation of the change score) and classified as minimal (< 0.20), small (0.20–0.49), medium (0.50–0.79), and large (≥ 0.80).

In a preplanned subgroup analysis of the primary outcome, the sample was restricted to patients not using non-AM adjunctive therapies during the first six study months. Adjunctive therapies analyzed were medications (Anatomical Therapeutic Chemical Classification Index: N06BA centrally acting sympathomimetics, N06A antidepressants), psychotherapy, occupational therapy, and play therapy. Post hoc subgroup analyses were performed on evaluable diagnostic groups and AM therapy modality groups.

Results
Participating physicians and therapists
The patients were enrolled by 19 physicians (16 general practitioners and three pediatricians). Comparing these physicians with AM-certified general practitioners and pediatricians in Germany without study patients (n = 282), no significant differences were found regarding gender (47.4% versus 57.1% males), age (mean 47.1 ± 6.4 versus 48.1 ± 8.0 years), number of years in practice (17.9 ± 7.0 versus 18.9 ± 8.8 years) or the proportion of physicians working in primary care (94.7% versus 98.6%).

The patients were treated by 30 different AM therapists (art, eurythmy, and rhythmical massage). Comparing these
therapists with certified AM therapists in Germany without study patients \((n = 1140)\), no significant differences were found regarding gender (76.7% versus 81.1% females), age (mean \(47.8 \pm 7.7\) versus \(50.3 \pm 9.5\) years) or the number of years since therapist qualification (10.8 \(\pm 6.8\) versus 13.1 \(\pm 8.7\) years).

### Patient recruitment and follow-up

From 01 April 2001 to 31 December 2005, a total of 69 patients aged 3–16 years starting AM therapy for ADHD symptoms were assessed for eligibility. Of these patients, 61 fulfilled all eligibility criteria and were included in the analysis. Eight patients were not included because of eligibility criteria not being fulfilled \((n = 2)\), because of previous study participation \([n = 1]\) and ongoing use of the trial AM therapy \([n = 1]\), patients’ baseline questionnaire missing \((n = 5)\), and physician’s baseline questionnaire received longer than two months after enrolment \((n = 1)\).

A total of 64% \((n = 39/61)\) of patients were enrolled by general practitioners and 36% \((n = 22/61)\) by pediatricians. The physicians’ settings were primary care practices (72% of evaluable patients, \(n = 41/57\)), referral practices (16%, \(n = 9\)), and outpatient clinics (28%, \(n = 16\)). Each physician enrolled 1–2 patients \((n = 12\) physicians\), 3–5 patients \((n = 3)\), or >5 patients \((n = 2)\), with a range of 1–16 patients enrolled per physician. The last patient follow-up was on 16 February 2008.

The parents were administered a total of 305 follow-up questionnaires, out of which 245 (80.3%) were returned. Follow-up rates were 95% \((n = 58/61)\), 87%, 77%, 72%, and 71% after three, six, 12, 18, and 24 months, respectively. At least one follow-up questionnaire was returned in 97% \((59/61)\) of patients.

Respondents \((n = 47)\) and nonrespondents \((n = 14)\) in the 12-month patient-follow-up did not differ significantly regarding age, gender, diagnosis, disease duration, baseline FBB-HKS total score, baseline disease score, or baseline symptom score. A corresponding comparison for the six-month follow-up was not performed because of the low number of nonrespondents \((n = 8)\). The corresponding comparison for the 24-month follow-up showed no significant differences regarding age, gender, diagnosis, disease duration, or baseline symptom score, while significant differences were found for baseline FBB-HKS total score \((0.43\) points higher in nonrespondents than in respondents, 95% confidence interval \([CI]: 0.16–0.70; P = 0.002\)) and baseline disease score \((1.25\) points higher in nonrespondents, 95% CI: 0.44–2.06; \(P = 0.003\)). The physician six-month follow-up documentation was available for 97% \((59/61)\) of patients.

### Baseline characteristics

#### Sociodemographic data

The patients were recruited from 11 of 16 German federal states. Mean age was 8.9 \(\pm 3.3\) years \((range 3.4–16.8)\); a total of 84% \((51/61)\) of the patients were boys. Mean household size, including the patient, was 3.9 \(\pm 1.2\) persons \((range 2–8)\). Further sociodemographic data are presented in Table 1.

#### Disease status

The duration of ADHD symptoms was 6–11 months in 3% \((n = 2/61)\) of patients, 1–4 years in 62% \((n = 38)\) and \(\geq5\) years in 34% \((n = 21)\), with a median symptom duration of 3.0 years \((range 0.5–10.0, mean 3.7 \pm 2.0\) years).

A total of 67% \((n = 41/61)\) of patients fulfilled the DSM-IV criteria for ADHD, 15% \((n = 9)\) had an exclusion diagnosis such as pervasive developmental disorders, and 18% \((n = 11)\) did not fulfill the ADHD criteria for another reason \((Table 2)\). A total of 28% \((n = 17/61)\) of patients fulfilled the ICD-10 research criteria for F90 hyperkinetic disorders. The FBB-HKS total score at baseline was 1.79 \(\pm 0.47\) in boys \((n = 50)\), 1.50 \(\pm 0.60\) in girls \((n = 10)\), and 1.74 \(\pm 0.50\) in the whole sample.

A current comorbid mental disorder \((ICD-10 F00-F99)\) was present in 17% \((n = 11/61)\) of patients, with F41 anxiety disorders in four patients and seven different other diagnoses in seven patients. A current comorbid physical diagnosis \((not ICD-10 F00-F99)\) was present in 57% \((35/61)\) of patients, with a median of 1.0 inter-

### Table 1: Sociodemographic data

<table>
<thead>
<tr>
<th>Item</th>
<th>n</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age groups</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3–5 years</td>
<td>9/61</td>
<td>15</td>
</tr>
<tr>
<td>6–9 years</td>
<td>34/61</td>
<td>56</td>
</tr>
<tr>
<td>10–15 years</td>
<td>16/61</td>
<td>26</td>
</tr>
<tr>
<td>16 years</td>
<td>2/61</td>
<td>3</td>
</tr>
<tr>
<td><strong>Living with</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mother</td>
<td>60/61</td>
<td>98</td>
</tr>
<tr>
<td>Father</td>
<td>38/61</td>
<td>62</td>
</tr>
<tr>
<td>Siblings</td>
<td>41/61</td>
<td>71</td>
</tr>
<tr>
<td>Other persons</td>
<td>8/61</td>
<td>13</td>
</tr>
<tr>
<td>More than one person</td>
<td>53/61</td>
<td>87</td>
</tr>
<tr>
<td><strong>School type</strong> (n = 47 school children)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>State school</td>
<td>21/47</td>
<td>45</td>
</tr>
<tr>
<td>Waldorf school</td>
<td>23/47</td>
<td>49</td>
</tr>
<tr>
<td>School for children with special needs (Förderschule)</td>
<td>2/47</td>
<td>4</td>
</tr>
<tr>
<td>Other school</td>
<td>1/47</td>
<td>2</td>
</tr>
<tr>
<td><strong>Health insurance coverage</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Statutory</td>
<td>55/60</td>
<td>92</td>
</tr>
<tr>
<td>Private</td>
<td>5/60</td>
<td>8</td>
</tr>
</tbody>
</table>
Among patients receiving medical treatment (n = 40), the duration of the consultation with the AM physician at study enrollment was 15–29 minutes (n = 16 patients), 30–44 minutes (n = 9), 45–59 minutes (n = 6), and ≥60 minutes (n = 9).

Among patients starting medical treatment (n = 40) a total of 56 different AM medications were prescribed at enrollment. The most frequent medications were Aurum/Stibium/Hyoscyamus pillules (prescribed to four patients), Aurum Comp pillules (n = 3) and Cichorium Plumbo Cultum Rh D3 liquid (n = 3). The most frequent starting materials were Aurum naturale (n = 12), Plumbum metallicum (n = 6), Cichorium intybus (n = 5), and Bryophyllum = Kalanchoe pinnata (n = 4).

Among the 57 patients referred to AM therapy, 89% (n = 51) had the planned AM therapy, while for 11% (n = 6) the AM therapy documentation is incomplete. AM therapies used were eurythmy therapy (n = 34 patients), rhythmical massage therapy (n = 5), and art therapy (n = 12) with the therapy modalities painting/drawing/clay (n = 2), speech exercises (n = 6), and music (n = 4). The AM eurythmy/art/massage therapy started at a median of six (IQR 2–21) days after enrolment. Median therapy duration was 102 days (IQR 79–203 days), and median number of therapy sessions was 13 (IQR 11–20). Median number of days between therapy sessions was eight days (IQR 6–11 days).

Conventional therapies
During the 12 months preceding study enrollment, central stimulants had been used by 15% (n = 9/61) of patients. In all cases, the stimulant used was methylphenidate (used for 10–12 months [n = 5], 1–4 months [n = 3], and unknown duration [n = 1]). During follow-up, stimulants were used by 10% (n = 6/61), 16% (n = 10), and 18% (n = 11) of patients in months 0–6, 0–12, and 0–24, respectively. In all cases, the stimulant used was methylphenidate. All six patients using methylphenidate in months 0–6 had used methylphenidate in the previous year. Grouping the patients according to the year of enrolment, the proportion of methylphenidate users in months 0–24 was 25% (n = 2/8), 14% (n = 3/22), 33% (n = 2/6), 17% (n = 2/12), and 15% (n = 2/13) in years 2001–2005. This proportion did not change significantly during the study (Kruskal–Wallis test, P = 0.823). Mean age for users and nonusers of methylphenidate in months 0–24 was 10.4 and 8.6 years, respectively (mean difference, 1.9 years, 95% CI: −0.1–3.8 years; P = 0.063). In patients with a DSM-IV diagnosis of ADHD (n = 41), the proportion of methylphenidate users was 15% (n = 4), 20% (n = 8), and 22% (n = 9) in months 0–6, 0–12, and 0–24, respectively.

### Table 2 Diagnoses in study participants

<table>
<thead>
<tr>
<th>ICD-10</th>
<th>Diagnosis</th>
<th>n</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>F90.0</td>
<td>ADHD, combined type</td>
<td>11</td>
<td></td>
</tr>
<tr>
<td>F90.0</td>
<td>ADHD, predominantly hyperactive-impulsive type</td>
<td>13</td>
<td></td>
</tr>
<tr>
<td>F98.8</td>
<td>ADHD, predominantly inattentive type</td>
<td>11</td>
<td></td>
</tr>
<tr>
<td>F90.9</td>
<td>ADHD, not otherwise specified</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>F94.9</td>
<td>Other reason for nonfulfillment of ADHD criteria</td>
<td>11</td>
<td>18</td>
</tr>
<tr>
<td>F94.9</td>
<td>ADHD symptoms beginning after age seven years</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>F94.9</td>
<td>ADHD symptoms not present in more than one setting (e.g., family, school, medical examination)</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>F94.9</td>
<td>No significant impairment in social, school, or work functioning</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>F94.9</td>
<td>ADHD symptoms explained by age and developmental condition or school strain</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>F94.9</td>
<td>ADHD symptoms explained by very high intelligence</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td>61</td>
<td>100</td>
</tr>
</tbody>
</table>

**Abbreviations:** ICD-10, International Statistical Classification of Diseases and Related Health Problems, 10th Revision; ADHD, attention deficit hyperactivity disorder; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition.

quartile range [IQR] 0–1, range 0–3) comorbid physical diagnoses. The most common comorbid physical diagnoses were R00-R99 symptoms, signs, and abnormal clinical and laboratory findings, not elsewhere classified (37%, 19/52 diagnoses), J00-J99 diseases of the respiratory system (13%, n = 7), and L00-L99 diseases of the skin and subcutaneous tissue (13%, n = 7). According to the physician, a mental disorder was suspected in one or both parents of 16% (n = 10/61) of patients, while familial instability or partner conflicts were suspected in 39% (n = 24).

### Therapy

**Anthroposophic therapies**

Patients received AM medical treatment alone (n = 4) or were referred to AM art, eurythmy, or rhythmical massage therapy without medical treatment (n = 21), or were referred to AM therapy with medical treatment (n = 36).
In the first six study months, 6% (n = 3/61) of all patients had psychotherapy, occupational therapy, or play therapy; 10% (n = 6) used methylphenidate, 0% used antidepressants, and 85% (n = 52) used none of these therapies.

Outcomes
Clinical outcomes
At six-month follow-up, all clinical outcomes were significantly improved from baseline (Table 3, Figures 1–3). Standardized response mean effect sizes for the 0–6 month comparison were large for disease and symptom scores, medium for FBB-HKS total, inattention and hyperactivity scores, and small for FBB-HKS impulsivity score and KINDL (Table 3).

The 0–6 month improvement of the FBB-HKS total score was analyzed in evaluable subgroups according to diagnosis, therapy, and school type (Table 4). Compared with all evaluable patients (mean improvement 0.30 points), patients with eurythmy therapy as their main therapy modality had 7% less improvement (0.30 → 0.28 points), patients fulfilling DSM-IV criteria for ADHD had 20% less improvement (0.30 → 0.24 points), and patients not using non-AM adjunctive therapies (see Methods for further description) had 17% more improvement (0.30 → 35 points). Among patients referred for AM art, eurythmy, or rhythmical massage therapy, the improvement was more pronounced in patients also receiving AM medical treatment, compared with patients not receiving medical treatment, but the difference was not significant (mean difference 0.10 points, 95% CI: −0.16–0.37 points; P = 0.434). Among schoolchildren, the improvement was similar in those attending Waldorf schools (0.31 points) and other schools (0.30). The 0–6 months improvement of the FBB-HKS total score showed a weak and nonsignificant positive correlation with age (Spearman-Rho = 0.24, P = 0.070).

At 24-month follow-up, all analyzed clinical outcomes (disease score was not documented beyond six-month follow-up) were significantly improved from baseline. Effect sizes for the 0–24 month comparison were large for FBB total and hyperactivity scores and symptom score, medium for FBB-HKS inattention score and KINDL, and small for FBB-HKS impulsivity score (Table 5).

Other outcomes
At six-month follow-up, parents’ average therapy outcome rating (numeric rating scale from 0 “no help at all” to 10 “helped very well”) was 6.29 ± 2.70, and parent satisfaction with therapy (numeric rating scale from 0 “very dissatisfied” to 10 “very satisfied”) was 7.45 ± 2.12. The parents’ effectiveness rating of eurythmy, art, or rhythmical massage therapy was positive (“very effective” or “effective”) in 68% (n = 34/50) of evaluable patients, and negative (“less effective”, “ineffective”, or “not evaluable”) in 32% (n = 16). The physicians’ effectiveness rating was positive in 84% (49/61) and negative in 16% (n = 9).

From 6- to 12-month follow-up, parent satisfaction with therapy decreased by average 1.32 points (95% CI: 0.55–2.10; P = 0.001), whereas the parents’ therapy outcome rating and the parents’ as well as the physicians’ effectiveness ratings did not change significantly.

Adverse reactions
The frequency of reported adverse drug reactions was 10% (3/31 users) for AM medications and 36% (4/11 users) for methylphenidate (P = 0.064). Adverse drug reactions of severe intensity were reported in one patient taking three different AM medications. Medication was stopped due to reported adverse reactions in two patients (AM medications, n = 1 and methylphenidate, n = 1). No adverse reactions from other medications or from nonmedication therapies occurred. No serious adverse events occurred.

Table 3 Clinical outcomes at 0–6 months

<table>
<thead>
<tr>
<th>Outcome (range)</th>
<th>n</th>
<th>0 months</th>
<th>6 months</th>
<th>0–6 months difference*</th>
<th>SRM</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Mean (SD)</td>
<td>Mean (SD)</td>
<td>Mean (95% CI)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>P</td>
</tr>
<tr>
<td>FBB-HKS (0–3)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>60</td>
<td>1.74 (0.50)</td>
<td>1.44 (0.53)</td>
<td>0.30 (0.18 to 0.43)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Inattention</td>
<td>60</td>
<td>1.87 (0.63)</td>
<td>1.52 (0.58)</td>
<td>0.36 (0.21 to 0.50)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Hyperactivity</td>
<td>61</td>
<td>1.60 (0.76)</td>
<td>1.31 (0.69)</td>
<td>0.29 (0.14 to 0.44)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Impulsivity</td>
<td>61</td>
<td>1.73 (0.84)</td>
<td>1.51 (0.83)</td>
<td>0.22 (0.03 to 0.40)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Symptom score (0–10)</td>
<td>60</td>
<td>6.51 (1.26)</td>
<td>4.85 (2.11)</td>
<td>1.66 (1.17 to 2.16)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Disease score (0–10)</td>
<td>60</td>
<td>7.07 (1.54)</td>
<td>4.73 (1.74)</td>
<td>2.33 (1.84 to 2.82)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>KINDL total quality of life (0–100)</td>
<td>58</td>
<td>63.95 (12.87)</td>
<td>69.32 (9.22)</td>
<td>5.37 (2.27 to 8.47)</td>
<td>0.001</td>
</tr>
</tbody>
</table>

Note: *Positive differences indicate improvement.
Abbreviations: CI, confidence interval; SD, standard deviation; SRM, standardized response mean effect size (minimal < 0.20; small 0.20–0.49; medium 0.50–0.79; large ≥ 0.80).
Anthroposophic therapy for ADHD

Discussion

The aim of this two-year prospective cohort study was to obtain information on AM therapy for children with ADHD symptoms under routine outpatient conditions in Germany. Two-thirds of the patients engaged in eurythmy movement exercises or artistic therapies, and two-thirds used AM medications. Patients were treated largely without stimulants (82% of patients). Under AM treatment, significant and sustained improvements in ADHD symptoms and quality of life were observed. AM therapies were well tolerated.

Strengths of this study include a long follow-up period, a standardized assessment of ADHD core symptoms as well as quality of life, and high representativeness. Patients were recruited from more than half of the German federal states, 91% of those screened and eligible were enrolled, and the participating physicians and therapists resembled eligible but not participating physicians and therapists with respect to demographic characteristics. These features suggest that the study mirrors contemporary AM therapy for ADHD symptoms in outpatient settings to a high degree.

Figure 1 FBB-HKS scores.

Note: Range: 0 “not present”, 3 “very strong intensity” (parents’ assessment, n = 60).
Because referral for AM treatment for ADHD symptoms is not dependent on the fulfillment of diagnostic criteria for ADHD,\textsuperscript{17,19} we included children with ADHD-related diagnoses and subsyndromal ADHD symptoms, as well as children fulfilling DSM-IV criteria for ADHD. The latter group was analyzed separately but had a modest sample size of 41 patients. Comparisons with other studies of DSM-IV-ADHD should therefore be interpreted with some caution. The fulfillment of ADHD diagnostic criteria was assessed by a validated checklist (DCL-HKS),\textsuperscript{51,52} and symptom severity was assessed with a validated questionnaire recommended for use in primary care (FBB-HKS).\textsuperscript{51,52} However, the physicians and parents did not receive special training in ADHD symptom rating. Also, the documentation did not include teacher ratings.

This analysis assessed AM as a whole system.\textsuperscript{50} Supplementary subgroup analysis was possible for patients referred for eurythmy therapy and similar improvement was documented in this group, while the sample size of the other therapy modality subgroups (art therapy, rhythmical massage therapy, AM medical therapy) did not allow for subgroup analysis. The influence of the AM therapy modality and other therapy variables (eg, duration of the consultation with the physician at study enrolment and number of AM therapy sessions) on clinical outcomes has been assessed in multivariate analyses of children in AMOS with ADHD symptoms and other chronic indications.\textsuperscript{49}

Because the study had a long recruitment period, the study physicians were not able to participate throughout the period and to screen and enroll all eligible patients. For a different subset of patients from the AMOS project (patients referred to AM therapies for any chronic indication and enrolled before April 1st, 2001), it was estimated that physicians enrolled every fourth eligible patient.\textsuperscript{58} This selection could bias the results if physicians were able to predict therapy response and if they preferentially screened and enrolled such patients for whom they expected a particularly favorable outcome. In this case, one would expect the degree of selection (ie, the proportion of eligible versus enrolled patients) to correlate positively with clinical outcomes, measured by the 0–12 month difference in symptom score. That was not the case, the correlation was almost zero (Spearman-Rho \(-0.04, P = 0.496, n = 364\)).\textsuperscript{58} Likewise, another analysis of 500 adult patients enrolled into AMOS in the period 1999–2005 showed no correlation between the degree of selection and the 0–6 month difference in symptom score (Hamre et al submitted for publication). These analyses do not suggest that the participating physicians’ expectations of future therapy response led to any selection bias affecting clinical outcomes.
Selection bias may also occur at the level of participation versus nonparticipation of eligible physicians, in that 94% of certified AM physicians treating children with ADHD symptoms did not enroll patients into the present sample. These nonparticipating physicians resembled the participating physicians with respect to demographics. We cannot, however, exclude differences in other aspects, such as the physicians’ preferred methods for treatment of ADHD symptoms.

A limitation of the study is the absence of a comparison group receiving conventional treatment or no therapy. Accordingly, one must consider several other possible causes for the observed improvements apart from the AM treatment. In order to address possible dropout bias, missing values were replaced by the last value carried forward.59 In a subgroup analysis of the FBB-HKS total score, the improvement was similar in patients not using adjunctive treatment, including stimulants. Therefore, adjunctive therapies cannot explain the improvement. Dietary modifications12,60 were not documented in the study and could therefore not be evaluated. During a two-year follow-up period, as in this study, some natural or developmental recovery of ADHD symptoms may occur.61 Regression to the mean due to symptom fluctuation with preferential self-selection to therapy and study inclusion at symptom peaks is another possibility. According to a previous analysis of mixed diagnoses from the AMOS project,59 this phenomenon could explain up to 14% of the improvement of disease score. Other possible confounders are psychologic factors and nonspecific effects (eg, placebo effects, context effects, physician-patient interactions, patient expectations, and social desirability effects). However, because AM therapy was evaluated as a whole system, the question of specific therapy effects versus nonspecific effects was not an issue in the present analysis.

The outcome analysis of this study comprised seven clinical outcome measures, including six outcomes analyzed at two follow-up assessments, ie, a total of 13 analyses (Tables 3 and 5). We did not use P value adjustment for multiple testing, which is a limitation in regard to the risk of find-

### Table 4 FBB-HKS total score subgroup analyses 0–6 months

<table>
<thead>
<tr>
<th>Group</th>
<th>n</th>
<th>0 months Mean (SD)</th>
<th>6 months Mean (SD)</th>
<th>0–6 month difference Mean (95% CI)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Main analysis: Patients with evaluable data at 0 months</td>
<td>60</td>
<td>1.74 (0.50)</td>
<td>1.44 (0.53)</td>
<td>0.30 (0.18–0.43)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Subgroups according to main therapy modality</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1. Eurythmy therapy with/without medical treatment</td>
<td>39</td>
<td>1.70 (0.51)</td>
<td>1.42 (0.54)</td>
<td>0.28 (0.12–0.44)</td>
<td>0.001</td>
</tr>
<tr>
<td>2. Eurythmy, art or rhythmical massage therapy with medical treatment</td>
<td>36</td>
<td>1.74 (0.48)</td>
<td>1.38 (0.50)</td>
<td>0.36 (0.20–0.51)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>3. Eurythmy, art or rhythmical massage therapy without medical treatment</td>
<td>21</td>
<td>1.68 (0.53)</td>
<td>1.43 (0.55)</td>
<td>0.25 (0.01–0.49)</td>
<td>0.042</td>
</tr>
<tr>
<td>Other subgroups</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4. Waldorf school pupils</td>
<td>23</td>
<td>1.72 (0.49)</td>
<td>1.40 (0.46)</td>
<td>0.31 (0.14–0.48)</td>
<td>0.001</td>
</tr>
<tr>
<td>5. Pupils of other schools</td>
<td>37</td>
<td>1.75 (0.52)</td>
<td>1.45 (0.58)</td>
<td>0.30 (0.12–0.47)</td>
<td>0.002</td>
</tr>
<tr>
<td>6. DSM-IV criteria for ADHD fulfilled</td>
<td>40</td>
<td>1.76 (0.47)</td>
<td>1.52 (0.53)</td>
<td>0.24 (0.09–0.39)</td>
<td>0.002</td>
</tr>
<tr>
<td>7. Patients not using stimulants, psychotherapy, occupational therapy, or play therapy in months 0–6</td>
<td>44</td>
<td>1.69 (0.52)</td>
<td>1.34 (0.52)</td>
<td>0.35 (0.20–0.50)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>8. Criteria 6 + 7</td>
<td>27</td>
<td>1.70 (0.49)</td>
<td>1.38 (0.53)</td>
<td>0.32 (0.14–0.50)</td>
<td>0.001</td>
</tr>
</tbody>
</table>

**Abbreviations:** ADHD, attention deficit hyperactivity disorder; CI, confidence interval; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition; SD, standard deviation.

### Table 5 Clinical outcomes at 0–24 months

<table>
<thead>
<tr>
<th>Outcome (range)</th>
<th>n</th>
<th>0 months Mean (SD)</th>
<th>24 months Mean (SD)</th>
<th>0–24 month difference* Mean (95% CI)</th>
<th>P value</th>
<th>SRM</th>
</tr>
</thead>
<tbody>
<tr>
<td>FBB-HKS (0–3)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>60</td>
<td>1.74 (0.50)</td>
<td>1.28 (0.61)</td>
<td>0.45 (0.31 to 0.59)</td>
<td>&lt;0.001</td>
<td>0.84</td>
</tr>
<tr>
<td>Inattention</td>
<td>60</td>
<td>1.87 (0.63)</td>
<td>1.43 (0.60)</td>
<td>0.44 (0.27 to 0.61)</td>
<td>&lt;0.001</td>
<td>0.65</td>
</tr>
<tr>
<td>Hyperactivity</td>
<td>61</td>
<td>1.60 (0.76)</td>
<td>1.07 (0.71)</td>
<td>0.53 (0.36 to 0.69)</td>
<td>&lt;0.001</td>
<td>0.80</td>
</tr>
<tr>
<td>Impulsivity</td>
<td>61</td>
<td>1.73 (0.84)</td>
<td>1.36 (0.91)</td>
<td>0.37 (0.17 to 0.56)</td>
<td>&lt;0.001</td>
<td>0.48</td>
</tr>
<tr>
<td>Symptom score (0–10)</td>
<td>60</td>
<td>6.51 (1.26)</td>
<td>4.41 (2.24)</td>
<td>2.09 (1.56 to 2.62)</td>
<td>&lt;0.001</td>
<td>1.02</td>
</tr>
<tr>
<td>KINDL total quality of life (0–100)</td>
<td>58</td>
<td>63.95 (12.87)</td>
<td>70.71 (10.99)</td>
<td>6.75 (3.51 to 10.00)</td>
<td>&lt;0.001</td>
<td>0.55</td>
</tr>
</tbody>
</table>

**Note:** Positive differences indicate improvement.

**Abbreviations:** CI, confidence interval; SD, standard deviation; SRM, standardized response mean effect size (minimal < 0.20; small 0.20–0.49; medium 0.50–0.79; large ≥ 0.80).
ing significant results by chance (Type I error). However, the problem of multiple testing has no universal solution, because $P$ value adjustment will increase the risk of Type II errors.\textsuperscript{55} The $P$ values in this study indicated significant improvements, with $P$ values $\leq 0.001$ in all analyses, a constellation that would not be expected to occur by chance (eg, a Bonferroni adjustment for 13 tests would have indicated $P < 0.004$ as the significance level).

Apart from two studies with five\textsuperscript{20} and 17 patients,\textsuperscript{46} respectively, this study provides the first data on the treatment of ADHD symptoms in AM settings. The higher prevalence of ADHD according to DSM-IV versus ICD-10 criteria (67\% versus 28\% of patients), as well as the overrepresentation of boys (84\%), are in accordance with the literature.\textsuperscript{3,8,62} Mental comorbidity was less frequent in our study (17\% of patients) than elsewhere (up to two-thirds),\textsuperscript{8} but an underestimation in our study cannot be excluded, because the documentation did not include a structured assessment of conduct disorders, learning disorders, and tics. Forty-four percent of patients in our study were assessed in specialist practice or in outpatient clinics. Similarly, in a large German administrative database, 36\% of children and adolescents with a claims diagnosis of ICD-10 F90 hyperkinetic disorder had seen a specialist at least once during the past year.\textsuperscript{63} Study documentation did include a structured assessment of conduct disorders, learning disorders, and tics. Forty-four percent of patients in our study had seen a specialist at least once during the past year.

The proportion of patients treated with stimulant medication (84\%) is in accordance with the literature.\textsuperscript{3,8,62} Mental comorbidity was less frequent in our study (17\% of patients) than elsewhere (up to two-thirds),\textsuperscript{8} but an underestimation in our study cannot be excluded, because the documentation did not include a structured assessment of conduct disorders, learning disorders, and tics. Forty-four percent of patients in our study were assessed in specialist practice or in outpatient clinics. Similarly, in a large German administrative database, 36\% of children and adolescents with a claims diagnosis of ICD-10 F90 hyperkinetic disorder had seen a specialist at least once during the past year.\textsuperscript{63} Study documentation did include a structured assessment of conduct disorders, learning disorders, and tics. Forty-four percent of patients in our study had seen a specialist at least once during the past year.

Baseline severity of ADHD symptoms, assessed by the FBB-HKS total score, was two standard deviations worse than average score values in German children aged 4–17 years.\textsuperscript{52} Symptom severity in our sample was higher in boys than in girls, which is similar to that in the general population.\textsuperscript{52} Quality of life at baseline assessed by KINDL total score was one standard deviation worse than average score values in German children aged 3–17 years, and approximately equal to the score of children classified as abnormal according to the Strengths and Difficulties Questionnaire.\textsuperscript{65} The proportion of patients treated with stimulant medication (16\% of all patients and 20\% of those with a DSM-IV diagnosis of ADHD in months 0–12) would seem to be lower than in Germany at the start of this study. In a large administrative dataset from the German Federal State of Hesse in year 2001, stimulants were prescribed to 25\% of children aged 3–15 years with a claims diagnosis of ICD-10 F90 hyperkinetic disorder.\textsuperscript{58} This comparison should be treated with some caution, because the database analysis did not include factors influencing stimulant prescription, such as ADHD diagnostic criteria, symptom severity, and comorbidity. During the study period, the prescription of methylphenidate in Germany was almost tripled (2001→2007: 16→46 million defined daily doses),\textsuperscript{67} an increase which was not reflected in our study. Possibly, families with children engaging in eurythmy or artistic exercises or other AM therapies might be less motivated to use stimulants.

In this study AM therapy was followed by improvement of ADHD symptoms and quality of life. This confirms previous findings.\textsuperscript{20,46} Symptom improvement in the first six months of this study, assessed by parents, amounted to one-half to two-third standard deviations for the FBB-HKS scores, which is similar to six-month results following other (non-AM) nonmedication therapies for ADHD.\textsuperscript{68,69} The corresponding improvement of symptom score was more pronounced, amounting to 1.3 standard deviations. Possible reasons for this discrepancy are differing scale constructions and constructs of the two instruments. The FBB-HKS (0–3 points) measures a broad range of ADHD symptoms, while symptom score (0–10 points) measures the individual symptoms deemed to be most important to each patient at baseline.

The AM approach evaluated in this study differs from many other therapies used for ADHD in two aspects. Whereas in many complementary\textsuperscript{12,70,71} and conventional therapies the child is essentially a passive user of products (eg, stimulants, herbs, homeopathic products or nutritional products) or recipient of treatments (eg, aromatherapy, chiropractic, or massage), the AM approach involves active as well as passive therapies. Whereas other active therapies (eg, behavioral interventions and neurofeedback) may be perceived as monotonous, the AM exercise therapies used by three-quarters of patients in this study allow for artistic movements (eurythmy) or expression (art therapy). This aspect of AM may be especially welcome in children with ADHD symptoms, many of whom are described as particularly artistic.\textsuperscript{42,72}

Future studies of AM treatment for ADHD symptoms should include a more detailed documentation of the AM therapy modalities (eg, for eurythmy therapy, the type of exercises used and the frequency and duration of home exercises). Studies with concurrent control groups would be desirable. However, it is difficult to conduct randomized trials in AM settings, because randomization is often rejected by AM physicians and their patients, chiefly due to strong therapy preferences.\textsuperscript{34,35} One possible solution could be to perform a pragmatic randomized trial, recruiting patients from outside AM settings and randomizing them to immediate treatment.
in an AM setting or to a waiting-list control group. Another possibility would be a nonrandomized system comparison of treatment by AM and conventional physicians with adjustment for baseline differences. In addition, there is scope for future qualitative studies exploring the experiences of families with children with ADHD symptoms undergoing AM treatment.

**Conclusion**

In this study, children with ADHD and ADHD-related conditions who received AM treatment had long-term reduction of symptoms and improvement of quality of life. The improvement was similar in children not using central stimulants. Although the pre–post design of the present study does not allow for conclusions about comparative effectiveness, study findings suggest that AM therapies may be useful in the long-term care of children with ADHD symptoms.

**Acknowledgments**

This study was funded by the Software-AG Stiftung and the Innungskrankenkasse Hamburg, with supplementary grants from the Christophorus-Stiftungsfonds in der GLS Treuhand e.V., the Mahle Stiftung, Wala Heilmittel GmbH, and Weleda AG. Our special thanks go to the study physicians, therapists, patients, and caregivers for participating.

**Disclosure**

Within the last five years HJJ and GSK have received restricted research grants and CM has received lecture fees from Wala and Weleda, manufacturers of AM medications. Otherwise, all authors declare that they have no competing interests.

**References**


38. List of Centers. Dornach: Council for Curative Education and Social Therapy; 2009.


